secwatch.observer — SEC 8-K summary
======================================

Issuer:     20/20 Biolabs, Inc. (AIDX)
CIK:        0001139685
Form:       8-K
Filed at:   2026-07-22T20:45:12+00:00
Accession:  0001213900-26-080432
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

20/20 Biolabs enters standstill with Streeterville; receives Nasdaq bid price deficiency notice
--------------------------------------------------------------------------------

- Standstill agreement with Streeterville: 120-day forbearance on conversion of Series E preferred unless stock price >10% above Nasdaq Minimum Price.
- Nasdaq notified company of non-compliance with $1.00 bid price rule for 30 consecutive business days through July 16, 2026.
- Company has 180 calendar days (until January 13, 2027) to regain compliance by closing bid price at $1.00 for 10 consecutive business days.
- If not compliant by Jan 13, 2027, may qualify for a second 180-day period if it meets other listing standards.
- Company intends to monitor bid price and consider available options to cure the deficiency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1139685/000121390026080432/0001213900-26-080432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1139685/000121390026080432/ea0298907-8k_2020bio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-080432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer